Craft

VBL Therapeutics

Stock Price

$0.2

2023-10-16

Market Capitalization

$12.1 M

2023-10-16

Revenue

$310 K

FY, 2023

VBL Therapeutics Summary

Company Summary

Overview
VBL Therapeutics (also known as Notable Labs, נוטבל לאבס, בע"מ; formerly Vascular Biogenics) is a biopharmaceutical company focused on the development of treatments for cancer. It offers VB-111, a gene-based biologic agent for solid tumor indications for ovarian cancer, recurrent glioblastoma, colon cancer, and thyroid cancer.
Type
Public
Status
Active
Founded
2000
HQ
Modi'in-Maccabim-Re'ut, IL | view all locations
Website
https://www.vblrx.com/
Cybersecurity rating
Sectors

Key People

  • Ruth Alon
  • Dror Harats

    Dror Harats, Founder, Director

    • David Hastings

      David Hastings, Director

      • Michael Rice

        Michael Rice, Director

        LocationsView all

        1 location detected

        • Modi'in-Maccabim-Re'ut, Center District HQ

          Israel

          Ha-Satat St 8

        VBL Therapeutics Financials

        Summary Financials

        Revenue (Q2, 2024)
        $2.0K
        Gross profit (Q2, 2024)
        $2.0K
        Net income (Q2, 2024)
        ($5.2M)
        Cash (Q2, 2024)
        $4.1M
        EBIT (Q2, 2024)
        ($5.3M)
        Enterprise value
        $8.3M

        Footer menu